App-Quantinova.ai

Identification of a new target patient population for ibrutinib treatment

S. Jordaens - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Ibrutinib

The clinical significance of FLT3‐ITD allele burden in AML – a long‐term retrospective single centre study

A. Duguid - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

L-Tyrosine

Platelet recovery after the first cycle of DA chemotherapy for AML is an independent predictor of survival

S. Sookramanien - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

N/A

Antibody immunotherapy treatment for adults with B‐acute lymphoblastic leukaemia–a real‐world analysis

T. Dexter - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cytokine release syndrome

Inotuzumab ozogamicin

Estimating the relative treatment effect and corresponding cost‐effectiveness estimates of inotuzumab ozogamicin versus blinatumomab for adults with Philadelphia chromosome‐negative relapsed/refractory B‐cell acute lymphoblastic leukaemia in the United Kingdom

T. A. Russell-Smith - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Inotuzumab ozogamicin

Incidence and management of PEGylated‐asparaginase related thrombosis in adults with ALL

M. Poynton - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Asparaginase

Spontaneous remission of acute myeloid leukaemia – how should this be handled by haematologists?

K. Milne - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

Lovan

Relapsed acute lymphoblastic leukaemia diagnosed using femoral head histology

J. Ryan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Avascular necrosis

Cyclophosphamide

19 courses of CPX‐351 for the treatment of AML

S. Boyd - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute myelocytic leukemia

daunorubicin + cytarabine

The role of nutrition in aggressive haematological malignancies – a single centre review of patients receiving intensive chemotherapy

G. McIlroy - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

N/A

The utility of flow cytometry in the diagnosis of acute monocytic and monoblastic leukaemia

I. Devanny - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute Leukemia

N/A

CAR‐T therapy as a curative option for childhood acute lymphoblastic leukaemia (ALL) in developing countries?

Z. Lim - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cytokine release syndrome

Tocilizumab

Evaluating Vyxeos use in routine clinical practice; data from the South East Scotland Cancer Network

V. Campbell - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

Daunorubicin

Single hospital retrospective review of patients in treatment‐free remission (TFR) following therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML)

S. Kundu - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

L-Tyrosine

Avascular necrosis diagnosed in young adults patients who had treatment for acute lymphoblastic leukaemia

C. Ghetu - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Avascular necrosis

Dexamethasone

Single centre experience in use of leukapheresis for management of leucostasis in high count leukaemia

N. Melamed - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Disseminated intravascular coagulation

N/A

The feasibility and impact of teaching haematology registrars via a web‐based videoconferencing system

T. Erblich - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

A toolkit for undertaking a volunteer OOPE/visit to a low resource country

M. Player - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Methadone hydrochloride

A little learning is a dangerous thing – how little do we know about when to treat pulmonary embolism?

M. Maybury - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Fondaparinux sodium

Real‐world data from the United Kingdom on the sequencing of second generation tyrosine kinase inhibitors for the treatment of chronic phase Philadelphia chromosome‐positive chronic myeloid leukaemia

J. Byrne - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Bosutinib

Filters

45280 Abstracts